You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Custom Sensor Manufacturing and Regulatory Preparation Assistance for Novel Intraoperative Ureter Detection Device

    SBC: BRITESEED, LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT The goal of this small business innovation research grant is to commercialize a cost-effective and contrast-free intraoperative ureter detection system, which integrates into a laparoscopic vessel sealing device to identify ureters in real-time and prevent iatrogenic injuries. 70% of iatrogenic ureteral injuries are detected postoperatively, up to 30 days after hospital di ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides

    SBC: MIDWEST BIOPROCESSING CENTER LLC            Topic: 300

    Project SummaryThe goal of the proposal presented herein is to produce naturally occurring 6-deoxysugars, including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized hexoses are found as important structural components throughout plant and microbial secondary metabolites, often playing a crucial role in conferring activity in bioactive natural products, such as ant ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Implantable Microarray Probe for Real-Time Glutamate and GABA Detection

    SBC: ALCORIX CO            Topic: 105

    Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Methods for Fast and Efficient Oxygen Imaging

    SBC: O2M TECHNOLOGIES LLC            Topic: 102

    Abstract Intermittent or acute/cyclic hypoxia in tumors, with frequencies between a few cycles per minute to hours, is receiving increased attention because this type of hypoxia has been reported to have an influence on tumor malignancy as well as treatment resistance via increased expression of pro-survival pathways. Fast oxygen imaging methods are needed for the measurement of acute tumor hypoxi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing NGF for Topical Treatment of Glaucoma

    SBC: HUMAN CELL CO            Topic: NEI

    ABSTRACTGlaucoma is a leading cause of irreversible vision loss, which is characterized by progressive degeneration of retinal ganglion cells (RGC) and their optic nerve axons. While age is a key risk factor, elevated intraocular pressure (IOP) is the only modifiable risk factor, with topical IOP-lowering drugs as the first line treatment. However, RGC degeneration and vision loss continues in hal ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Selective Activators of Nrf2 for Neurodegenerative Disease

    SBC: GROVE BIOPHARMA, INC.            Topic: 105

    Protein-like polymers (PLPs) are next generation biotherapeutics with the potential to improve treatment outcomes for patients suffering from devastating neurodegenerative diseases. We have developed a lead PLP that disrupts the Keap1-Nrf2 intracellular protein-protein interaction (PPI) that restricts the therapeutic activity of Nrf2 (nuclear factor-erythroid factor 2-related factor 2), a validate ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Mature brain organoid platform for therapeutic screening for ALS/FTD

    SBC: SYNAPTICURE INC            Topic: 105

    Abstract Synapticure is developing a novel patient-derived 3D platform for high-fidelity modeling and screening of TDP- 43 proteinopathy and associated biomarkers for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Synapticure’s mature brain organoids (mbOrgs) are composed of key neural cells derived from patient- induced pluripotent stem cells (iPSCs) and are custom assem ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government